Adaptive Biotechnologies (ADPT) Non-Current Debt (2022 - 2026)

Adaptive Biotechnologies has disclosed Non-Current Debt across 5 years of filings, most recently posting $124.7 million for Q1 2026.

• Non-Current Debt for Q1 2026 came in at $124.7 million, down 5.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $124.7 million (down 5.17% YoY), and the FY2025 annual result was $126.6 million, down 4.42% from the prior year.
• Non-Current Debt came in at $124.7 million for Q1 2026 at Adaptive Biotechnologies, down from $126.6 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $132.7 million in Q3 2024 to a low of $124.7 million in Q1 2026.
• The 5-year median for Non-Current Debt is $130.6 million (2023), against an average of $129.5 million.
• Across the five-year window, Non-Current Debt climbed 4.71% in 2024 and retreated 5.17% in 2026, its largest moves.
• Adaptive Biotechnologies' Non-Current Debt stood at $125.4 million in 2022, then climbed by 4.23% to $130.7 million in 2023, then rose by 1.34% to $132.4 million in 2024, then fell by 4.42% to $126.6 million in 2025, then retreated by 1.44% to $124.7 million in 2026.
• The last three Non-Current Debt figures came in at $124.7 million (Q1 2026), $126.6 million (Q4 2025), and $129.4 million (Q3 2025), per Business Quant data.